Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Inc. completed the acquisition of TeneoBio, Inc. from Lightspeed Ventures, LLC and Sutter Hill Ventures.

10/19/2021 EST

Amgen Inc. (NasdaqGS:AMGN) announced an agreement to acquire TeneoBio, Inc. from Lightspeed Venture Partners, Sutter Hill Ventures and others for $2.5 billion on July 27, 2021. The purchase price is subject to customary adjustments. Under the terms of the agreement, Amgen will acquire all outstanding shares of Teneobio at closing in exchange for a $900 million upfront cash payment, as well as future contingent milestone payments to Teneobio equity holders potentially worth up to an additional $1.6 billion in cash. The acquisition is subject to customary closing conditions, including applicable regulatory approvals, antitrust approvals and Teneobio?s completion of certain restructuring arrangements with respect to its subsidiaries, including the spin out of three of Teneobio?s subsidiaries to the pre-closing equity holders of Teneobio and the closing of AbbVie Inc.?s acquisition of TeneoOne, Inc. The transaction is expected to close in the second half of 2021. Goldman Sachs & Co. LLC acted as financial advisor and Daniel Rees, Charles Ruck, Steve Chinowsky, Darryl Steensma, Eliot Choy, Michelle Carpenter, Larry Stein, William Kessler, Elizabeth Richards, Robert Blamires, Mandy Reeves and Patrick English of Latham & Watkins LLP acted as legal advisors to Amgen. Michael Irvine, Michael Richman, Steve Ray, Colin Chapman and Craig Olshan of Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP acted as legal advisors to TeneoBio. Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of TeneoBio, Inc. from Lightspeed Ventures, LLC and Sutter Hill Ventures on October 19, 2021.


ę S&P Capital IQ 2021
All news about AMGEN INC.
12/03AMGEN : Bradway Hails Amgen's Progress Against 'Undruggable' Disease Targets at Two Health..
PU
12/03Amgen Raises Fiscal Q1 Dividend 10% to $1.94 a Share, Payable March 8 to Shareholders o..
MT
12/03Amgen Announces 10% Increase In 2022 First Quarter Dividend
PR
12/03Amgen Declares 2022 First Quarter Dividend, Payable on March 8, 2022
CI
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/01Amgen Arthritis Drug Shows Promise as Psoriasis Medication During Phase III Testing
MT
12/01Amgen Announces Positive Top-Line Results From Otezla« (apremilast) Phase 3 DISCREET St..
PR
12/01Amgen Inc. Announces Positive Top-Line Results From Otezla? Phase 3 DISCREET Study In M..
CI
12/01Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
MT
12/01Amgen Gets FDA Nod for New Kyprolis Combo Regimen for Multiple Myeloma
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 018 M - -
Net income 2021 5 551 M - -
Net Debt 2021 22 411 M - -
P/E ratio 2021 20,5x
Yield 2021 3,44%
Capitalization 114 B 114 B -
EV / Sales 2021 5,24x
EV / Sales 2022 4,92x
Nbr of Employees 24 300
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 202,44 $
Average target price 238,86 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-11.95%114 028
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641